APA (7th ed.) Citation

Gaeckler, A., Al‐Dakkak, I., Saval, N., Dieperink, H. H., Eygenraam, M., Greenbaum, L. A., . . . Walle, J. V. (2025). Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. Wiley. https://doi.org/10.1111/ctr.70278

Chicago Style (17th ed.) Citation

Gaeckler, Anja, Imad Al‐Dakkak, Nuria Saval, Hans Herman Dieperink, Margriet Eygenraam, Larry A. Greenbaum, Nicole Isbel, and Johan Vande Walle. Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global AHUS Registry Analysis. Wiley, 2025. https://doi.org/10.1111/ctr.70278.

MLA (9th ed.) Citation

Gaeckler, Anja, et al. Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global AHUS Registry Analysis. Wiley, 2025. https://doi.org/10.1111/ctr.70278.